Cell Therapeutics may finally get win for embattled pixantrone in April 2012
This article was originally published in Scrip
Executive Summary
Shares of Cell Therapeutics soared as high as 24.3% on 6 December on word that the US FDA accepted the firm's resubmission of its application for pixantrone as a single-agent treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy – setting 24 April 2012 as the new Prescription Drug User Fee Act action date.